Randox and SCIENION Expand Collaboration for Scaling-Up of Biochip and SARS CoV2 Test Manufacturing

Their joint activities will include co-working at Randox and at SCIENION headquarters, including massive scaling-up of SARS CoV2 test manufacturing. In addition to focusing on a single core objective of increasing Randox manufacturing capacity for biochips significantly and immediately, the strategic alliance will also involve collaboration between the two companies to develop and apply next-generation diagnostics platforms and processes that support future key programs.

“As Randox continues evolving into a focused diagnostics company powered by advanced multiplexed tests and data science, alliances like this will help us deliver on our goal to improve healthcare worldwide,” said John Lamont, Director of R&D at Randox Laboratories. “Pairing our deep understanding of diagnostics with SCIENION’s leading expertise in high throughput microarray manufacturing, this could transform the way we discover and develop diagnostic tests for the world.”

“Our strategic alliance will combine Randox Diagnostics expertise with the power of SCIENION precision liquid handling and sciFLEXARRAYER S100 technology,” said Dr. Andrew Sweet, managing director of SCIENION UK Ltd. “Together, we aim to address some of the biggest challenges facing the life sciences industry today. This would quickly bring reliable rapid diagnostic testing technology to the frontline for widespread use in all affected regions during a pandemic such as SARS-CoV2.”